Pediatric Dermatology

Pediatric Dermatology

Pediatric dermatology is a branch of dermatology that specializes in identifying and treating skin conditions in newborns, young children, and teenagers. Children can acquire a variety of skin disorders, from less dangerous conditions like skin cancer to more significant ones like eczema and acne. Therefore, the rising prevalence of skin disorders in pediatrics drives the growth of the pediatric dermatology treatment market. In addition, skin disorders in infants are different from skin disorders in adults such as erythema toxicum neonatorum is only seen in newborns. The National Institute of Health stated that, in 2022, about 48 to 72 percent of full-term infants develop erythema toxicum neonatorum, a benign, self-limited, temporary, and evanescent eruption.

The Pediatric Dermatology Treatment Market is expected to grow at a strong CAGR of xx during the forecast period owing to the rising use of technologically advanced medical devices for the treatment of pediatric dermatology conditions. The pediatric dermatology treatment market is significantly expanding due to the increased prevalence of skin disorders, particularly alopecia, and psoriasis, rising public awareness of these conditions, and an increase in the use of laser therapy.

• Based on drug class, the market is segmented into anti-infectives, corticosteroids, anti-acne, calcineurin inhibitors, retinoids, and others. Amongst these, the anti-infectives segment dominated the market in 2021. This is because of the surge in awareness of the anti-infectives effectiveness in treating skin infections. The accessibility of anti-infective products also increases access to care for pediatric patients with skin infections. For instance, in February 2023, Pfizer's supplemental New Drug Application for CIBINQO was approved by FDA, which provides the new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis.
• By application, the market is segmented into alopecia, erythromelalgia, psoriasis, atopic dermatitis, and others. Among these, alopecia is expected to grow with a significant CAGR during the forecast period. This is mainly due to the rising genetic disorders, and certain medical conditions, such as autoimmune disorders, can cause hair loss in children.
• On the basis of end-users, the market is segmented into hospitals, clinics, cosmetic centers, and others. Cosmetic centers are expected to grow with a significant CAGR during the forecast period owing to the popularity of cosmetic procedures increasing continuously, and as people become more aware and want the highest qualified surgeons to perform the treatments, and are willing to spend more money on the treatments as well.
• For a better understanding of the market adoption of the pediatric dermatology treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Rest of World. North America dominated the pediatric dermatology treatment market in 2021 due to major factors such as favorable government initiatives, growing awareness of skin conditions among parents and healthcare providers, increased investments in research and development for pediatric dermatology treatment coupled with technological advancements, and the rapid increase in the large pediatric population are propelling the growth of this market in the region. For example, According to the World Bank report, in 2022, the number of United States aged 0-14 has 18% of the total population.
• Some of the major players operating in the market include Novartis AG; Amgen Inc.; AbbVie Inc.; Almirall S.A; Bausch Health Companies Inc.; Pfizer Inc.; Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Sanofi S.A.; Bristol Myers Squibb Company.